Shi Lipeng, Du Xuqin, Zuo Biao, Hu Jinyuan, Cao Wenfu
College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China.
Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing 400016, China.
Evid Based Complement Alternat Med. 2022 Jul 20;2022:2894659. doi: 10.1155/2022/2894659. eCollection 2022.
The composition and metabolic activities of gut microbiota are strongly interconnected with cardiac fibrosis (CF) and heart failure (HF). Qige Huxin formula (QHF), a traditional Chinese medicine (TCM) formulation originating from a classical Fangji Huangqi decoction, has been widely used to clinically treat HF for decades. However, it is still unclear whether QHF alleviates CF by modulating gut microbiota and intestinal integrity.
This study aimed to investigate the cardioprotective effects of QHF in isoprenaline-induced CF through modulating gut microbiota and intestinal integrity.
Fifty mice were randomly divided into five groups after one week of acclimatization feeding: control group, model group, 2.56 g/kg/d group (low-dose QHF), 5.12 g/kg/d group (high-dose QHF), and meto group (15 mg/kg/d). The CF model was established by subcutaneously injecting the mice with isoprenaline (10 mg/kg/d for 14 days), followed by QHF treatment. The heart volume, cardiac weight index (CWI), serum myocardial enzymes, serum inflammatory cytokines, serum lipopolysaccharide, histopathology of the heart and colon tissues, ZO-1, and occludin of colon tissues were then measured. Fecal samples from mice were analyzed using 16S rRNA sequencing.
QHF treatment significantly reduced heart volume, CWI, and serum CK and CK-MB levels, attenuated cardiac histopathological alterations, and alleviated CF. QHF treatment also downregulated TNF-, IL-1, and IL-6 in serum. Moreover, QHF treatment decreased the serum level of lipopolysaccharide and maintained intestinal integrity by upregulating ZO-1 and occludin. The 16S rRNA microbiota analysis revealed that QHF treatment increased the relative abundance of and .
QHF treatment exerts cardioprotective effects through modulating gut microbiota, protecting intestinal integrity, and alleviating inflammation. This study shows that gut microbiota may enhance heart-gut interaction.
肠道微生物群的组成和代谢活动与心脏纤维化(CF)和心力衰竭(HF)密切相关。芪苈强心方(QHF)是一种源自经典方剂黄芪汤的中药制剂,数十年来一直被广泛用于临床治疗HF。然而,QHF是否通过调节肠道微生物群和肠道完整性来减轻CF仍不清楚。
本研究旨在探讨QHF通过调节肠道微生物群和肠道完整性对异丙肾上腺素诱导的CF的心脏保护作用。
适应性喂养1周后,将50只小鼠随机分为5组:对照组、模型组、2.56 g/kg/d组(低剂量QHF)、5.12 g/kg/d组(高剂量QHF)和米托组(15 mg/kg/d)。通过皮下注射异丙肾上腺素(10 mg/kg/d,共14天)建立CF模型,随后进行QHF治疗。然后测量心脏体积、心脏重量指数(CWI)、血清心肌酶、血清炎症细胞因子、血清脂多糖、心脏和结肠组织的组织病理学、结肠组织的ZO-1和闭合蛋白。使用16S rRNA测序分析小鼠的粪便样本。
QHF治疗显著降低了心脏体积、CWI以及血清CK和CK-MB水平,减轻了心脏组织病理学改变,并缓解了CF。QHF治疗还下调了血清中的TNF-、IL-1和IL-6。此外,QHF治疗降低了血清脂多糖水平,并通过上调ZO-1和闭合蛋白维持了肠道完整性。16S rRNA微生物群分析显示,QHF治疗增加了 和 的相对丰度。
QHF治疗通过调节肠道微生物群、保护肠道完整性和减轻炎症发挥心脏保护作用。本研究表明肠道微生物群可能增强心-肠相互作用。